AGHD is characterized by diminished growth hormone (GH) secretion by the pituitary gland. This can be have many causes, including the presence of a pituitary tumor, other growths/disorders in the pituitary or hypothalamic area, history of surgery or radiation therapy to the pituitary area or base of skull, or head trauma. In these situations, reduced GH secretion in children leads to short stature. In adults, the clinical syndrome includes:
Altered body composition (increased fat mass, decreased lean body mass)
Decreased muscle strength
Altered lipid profile
Decreased bone mineral density
Diminished quality of life, characterized by low energy level, increased emotional lability and irritability, and increased social isolation
Enhanced cardiovascular risk
In children: short stature
GH appears to be one of the first hormones to be lost in patients with pituitary tumors and nearly all patients with two or more other pituitary deficiencies also lack GH.
Clinical Trials for Adult Growth Hormone Deficiency
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Adult Growth Hormone Deficiency Growth hormone is a necessity for normal brain function. A deficiency is a result from pituitary tumors and is called adult growth hormone deficiency (AGHD). Adult Growth Hormone DeficiencyAGHD